Who
Bryan J. McMichael
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Coherus Oncology.
In numbers
- Trades disclosed
- 44
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 7 Sep 2022
- Last trade
- 29 May 2026
- Last filed
- 2 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code D | —100,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code D | —25,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code D | —15,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code D | —100,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code D | —25,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code D | —15,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code D | —25,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code D | —25,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code D | —30,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code D | —25,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code D | —25,000 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.